Mediastinal Lymphoma — Trials

Mediastinal Lymphoma — Trials · CancerIndex

Clinical trials

Registered studies

141 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.

Active: 63
Recruiting: 36
Ph III recruiting: 1
Growth YoY: —
Industry share: 22%
Top sponsor: University of Washington
Termination share: 26.8%

Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancers Terminated studies (13)

clinicaltrialsPublishedShowing 1–2 of 2 studies matching the filters · status and phase as posted by the registrant; each row links to the study record.

NCT	Title	Status	Phase	Enrollment (n)	Sponsor	Countries	Last update	Source
NCT04759586	Nivolumab in Combination With Chemo-Immunotherapy for the Treatment of Newly Diagnosed Primary Mediastinal B-Cell Lymphoma	active not recruiting	Phase 3	244	National Cancer Institute (NCI)NIH	4	Sep 10, 2026	clinicaltrials
NCT06188676	Multicenter Study of Safety and Efficacy Nivolumab at the Fixed Dose 40 mg (Nivo40) in Combination With Chemo-Immunotherapy for the Treatment of Newly Diagnosed PMBL	recruiting	Phase 3	100	National Research Center for Hematology, RussiaNETWORK	1